Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (11-20 of 953) with videos related to

Pageof 96
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 10, 2009
Can we do better in developing new drugs for Alzheimer's disease?Serge Gauthier, Philip Scheltens
Neurobiology of Aging|May 29, 2004
Biomarkers for Alzheimer's disease. Which way to go?Charlotte E Teunissen, Philip Scheltens
The Lancet. Neurology|November 23, 2007
Use of proteomic approaches to identify disease biomarkersCharlotte E Teunissen, Philip Scheltens
Nature Reviews. Neurology|February 18, 2015
White matter hyperintensities, cognitive impairment and dementia: an updateNiels D Prins, Philip Scheltens
Practical Neurology|July 18, 2009
Dementia: the bare essentialsMaartje I Kester, Philip Scheltens
Neurology|December 23, 2011
MRI-based biomarkers of preclinical AD: an Alzheimer signatureSusan M Resnick, Philip Scheltens
Alzheimer'S Research & Therapy|November 13, 2013
Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the futureNiels D Prins, Philip Scheltens
International Psychogeriatrics|September 30, 2005
White-matter changes on MRI as surrogate markerPhilip Scheltens, Frederik Barkhof, Franz Fazekas
Nederlands Tijdschrift Voor Geneeskunde|December 12, 2013
[Medical nutrition in Alzheimer's: the trials]Philip Scheltens, Jos W R Twisk
Dementia and Geriatric Cognitive Disorders Extra|December 7, 2016
Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: 'Growing into Deficits'Marlijn H de Beer, Philip Scheltens
Pageof 96

Showing results (11-20 of 953) with videos related to

Sort By:
Pageof 96
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 10, 2009
Can we do better in developing new drugs for Alzheimer's disease?Serge Gauthier, Philip Scheltens
Neurobiology of Aging|May 29, 2004
Biomarkers for Alzheimer's disease. Which way to go?Charlotte E Teunissen, Philip Scheltens
The Lancet. Neurology|November 23, 2007
Use of proteomic approaches to identify disease biomarkersCharlotte E Teunissen, Philip Scheltens
Nature Reviews. Neurology|February 18, 2015
White matter hyperintensities, cognitive impairment and dementia: an updateNiels D Prins, Philip Scheltens
Practical Neurology|July 18, 2009
Dementia: the bare essentialsMaartje I Kester, Philip Scheltens
Neurology|December 23, 2011
MRI-based biomarkers of preclinical AD: an Alzheimer signatureSusan M Resnick, Philip Scheltens
Alzheimer'S Research & Therapy|November 13, 2013
Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the futureNiels D Prins, Philip Scheltens
International Psychogeriatrics|September 30, 2005
White-matter changes on MRI as surrogate markerPhilip Scheltens, Frederik Barkhof, Franz Fazekas
Nederlands Tijdschrift Voor Geneeskunde|December 12, 2013
[Medical nutrition in Alzheimer's: the trials]Philip Scheltens, Jos W R Twisk
Dementia and Geriatric Cognitive Disorders Extra|December 7, 2016
Cognitive Decline in Patients with Chronic Hydrocephalus and Normal Aging: 'Growing into Deficits'Marlijn H de Beer, Philip Scheltens
Pageof 96